New Delhi, Aug. 6 -- A Parliamentary Standing Committee has recommended a review of the pricing framework for non-scheduled medicines, while asking the government to examine the feasibility of reintroducing cost-based pricing in cases where significant price disparities or unusually high mark-ups are observed.

The recommendations are part of the 33rd Report of the Standing Committee on Chemicals and Fertilizers on the role, functions and duties of the National Pharmaceutical Pricing Authority (NPPA). The report was presented in the Lok Sabha on Thursday.

The committee noted that nearly 82 per cent of the pharmaceutical market comprises non-scheduled formulations, whose prices are fixed by manufacturers, while the NPPA only monitors pric...